首页> 外国专利> A pharmaceutical formulation of palbociclib and a preparation method thereof

A pharmaceutical formulation of palbociclib and a preparation method thereof

机译:palbociclib的药物制剂及其制备方法

摘要

The present invention relates to a pharmaceutical composition of palbociclib in the form of an amorphous solid dispersion for use in the treatment of breast cancer, such as metastatic breast cancer. The amorphous solid dispersion comprising: palbociclib or a pharmaceutically acceptable salt thereof; an acidic auxiliary material comprising more than one pharmaceutically acceptable acid, at least one of which is an organic acid; and a hydrophilic high molecular weight material. The acidic auxiliary material may comprise one or more pharmaceutically acceptable inorganic acids as well as the at least one organic acid. The pharmaceutically acceptable organic acid may be tartaric acid, fumaric acid, succinic acid, citric acid, lactic acid, malic acid, an aliphatic sulfonic acid, or an aromatic sulfonic acid. The aliphatic sulfonic acid may be methanesulfonic acid, ethanesulfonic acid, or isethionic acid. The aromatic sulfonic acid may be benzenesulfonic acid or p-toluenesulfonic acid. The pharmaceutically acceptable inorganic acid may be hydrochloric acid, sulfuric acid, or phosphoric acid. The hydrophilic high-molecular weight material may be povidone K30, copovidone VA64 (PVP VA64), Soluplus, hydroxypropylmethylcellulose E5, hydroxypropylmethylcellulose acetate succinate, hydroxypropyl-β-cyclodextrin, or sulfobutyl ether-β-cyclodextrin. The mass ratio of the high molecular weight material to palbociclib may be from 0.1:1 to 10:1 and the mass ration of the acidic auxiliary material to palbociclib may be from 0.2:1 to 5:1. The dissolution rate of the palbociclib or pharmaceutically acceptable salt thereof in a solution of pH 6.0 may be greater than 60 % over a time period of 60 minutes, or greater that 50 % over a time period of 5 minutes. The amorphous solid dispersion may be stable for at least one week when stored at a temperature of 40 °C and humidity of about 75 %.
机译:本发明涉及无定形固体分散体形式的palbociclib的药物组合物,其用于治疗乳腺癌,例如转移性乳腺癌。该无定形固体分散体包含:palbociclib或其药学上可接受的盐;和一种酸性辅助材料,其包含一种以上的药学上可接受的酸,其中至少一种是有机酸;和亲水性高分子量材料。酸性辅助材料可包含一种或多种药学上可接受的无机酸以及至少一种有机酸。药学上可接受的有机酸可以是酒石酸,富马酸,琥珀酸,柠檬酸,乳酸,苹果酸,脂族磺酸或芳族磺酸。脂族磺酸可以是甲磺酸,乙磺酸或羟乙磺酸。芳族磺酸可以是苯磺酸或对甲苯磺酸。药学上可接受的无机酸可以是盐酸,硫酸或磷酸。亲水性高分子材料可以是聚维酮K30,共聚维酮VA64(PVP VA64),Soluplus,羟丙基甲基纤维素E5,羟丙基甲基纤维素乙酸丁二酸酯,羟丙基-β-环糊精或磺丁基醚-β-环糊精。高分子量材料与palbociclib的质量比可以为0.1∶1至10∶1,并且酸性辅助材料与palbociclib的质量比可以为0.2∶1至5∶1。 palbociclib或其药学上可接受的盐在pH 6.0的溶液中的溶解速率在60分钟的时间内可以大于60%,或者在5分钟的时间内大于50%。当在40℃的温度和约75%的湿度下存储时,无定形固体分散体可以稳定至少一周。

著录项

  • 公开/公告号GB2583425A

    专利类型

  • 公开/公告日2020-10-28

    原文格式PDF

  • 申请/专利权人 SHENZHEN PHARMACIN CO. LTD.;

    申请/专利号GB20200010241

  • 发明设计人 ZEREN WANG;JUN XU;LONG QU;

    申请日2016-06-21

  • 分类号A61K31/519;A61K9/10;A61K47/02;A61K47/12;A61K47/26;A61K47/32;A61K47/36;A61K47/38;A61P35;

  • 国家 GB

  • 入库时间 2022-08-21 10:59:46

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号